Published in Cancer Chemother Pharmacol on January 01, 1992
In Vivo Feasibility of Electrostatic Precipitation as an Adjunct to Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC). Ann Surg Oncol (2016) 0.83
Successful surgical approach for a patient with encapsulating peritoneal sclerosis after hyperthermic intraperitoneal chemotherapy: a case report and literature review. BMC Surg (2014) 0.78
Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst (1998) 3.67
Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology (1996) 3.54
Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med (1987) 3.04
MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol (2001) 2.71
[Effects and costs of adjuvant chemotherapy for operable lymph node positive breast cancer with HER2/neu overexpression]. Ned Tijdschr Geneeskd (2006) 2.65
Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol (1996) 2.61
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol (2005) 2.39
Quality of life in colorectal cancer. Stoma vs. nonstoma patients. Dis Colon Rectum (1995) 2.15
Decision analysis in the management of duodenal adenomatosis in familial adenomatous polyposis. Gut (1997) 1.88
Dermatofibrosarcoma protuberans: treatment and prognosis. Eur J Surg Oncol (1992) 1.87
Gastric non-Hodgkin lymphomas of mucosa-associated lymphoid tissue are not associated with more aggressive Helicobacter pylori strains as identified by CagA. Am J Clin Pathol (1996) 1.84
Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. Ann Oncol (2002) 1.80
Anatomy and physiology of lymphatic drainage of the breast from the perspective of sentinel node biopsy. J Am Coll Surg (2001) 1.79
Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin. Ann Oncol (2002) 1.78
Reliability of sentinel lymph node biopsy for staging melanoma. Br J Surg (2000) 1.71
The molecular genetics of human lung cancer. Eur Respir J (1989) 1.64
Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J Natl Cancer Inst (1991) 1.64
Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: effect of graft size. Ann Oncol (1994) 1.56
Positive iliac and obturator nodes in melanoma: survival and prognostic factors. Ann Surg Oncol (1999) 1.55
Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs. J Am Coll Surg (1996) 1.54
Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer (2003) 1.50
Lymph node metastasis from melanoma with an unknown primary site. Br J Surg (1990) 1.49
A cost-effectiveness analysis of colorectal screening of hereditary nonpolyposis colorectal carcinoma gene carriers. Cancer (1998) 1.49
Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver. Int J Cancer (1991) 1.47
Clear cell sarcoma (malignant melanoma) of soft parts: A clinicopathologic study of 30 cases. Cancer (1999) 1.46
[Identification of the sentinel node in patients with breast carcinoma]. Ned Tijdschr Geneeskd (1996) 1.42
At home management of aplastic phase following high-dose chemotherapy with stem-cell rescue for hematological and non-hematological malignancies. Ann Oncol (1999) 1.41
The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol (2010) 1.38
Septic melioidosis after a visit to Southeast Asia. Eur J Clin Microbiol (1986) 1.38
[Favorable effect of hematopoietic stem cells isolated from blood on hematologic recovery following high-dosage chemotherapy]. Ned Tijdschr Geneeskd (1993) 1.38
Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol (2002) 1.37
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol (2010) 1.35
The risk of brain tumours in hereditary non-polyposis colorectal cancer (HNPCC). Int J Cancer (1996) 1.35
Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann Oncol (1998) 1.35
Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Ann Oncol (2001) 1.33
Histological grading in gastric lymphoma: pretreatment criteria and clinical relevance. Gastroenterology (1997) 1.30
Expression of oestrogen receptor and loss of E-cadherin are diagnostic for gastric metastasis of breast carcinoma. Histopathology (2005) 1.27
Evaluation of mammary lymphoscintigraphy by a single intratumoral injection for sentinel node identification. J Nucl Med (2000) 1.25
Resectable retroperitoneal soft tissue sarcomas. The effect of extent of resection and postoperative radiation therapy on local tumor control. Cancer (1994) 1.25
Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery (1994) 1.23
Patient motivation and informed consent in a phase I study of an anticancer agent. Eur J Cancer Clin Oncol (1984) 1.23
Frozen section investigation of the sentinel node in malignant melanoma and breast cancer. Ann Surg Oncol (2001) 1.19
Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients. Br J Cancer (2003) 1.19
Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers. Br J Cancer (2013) 1.17
High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy. Br J Cancer (2006) 1.16
Comparison of immunocytochemistry, reverse transcriptase polymerase chain reaction, and nucleic acid sequence-based amplification for the detection of circulating breast cancer cells. Breast Cancer Res Treat (1999) 1.16
The definition of a sentinel node. Ann Surg Oncol (2001) 1.15
Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy. Ann Oncol (2010) 1.15
C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest (1994) 1.13
Localizing the sentinel node in cutaneous melanoma: gamma probe detection versus blue dye. Ann Surg Oncol (1997) 1.13
Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics. Breast Cancer Res Treat (2011) 1.12
Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy. Br J Cancer (2006) 1.12
Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol (1988) 1.10
Clinical heterogeneity of familial colorectal cancer and its influence on screening protocols. Gut (1994) 1.09
Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol (1993) 1.07
Surgery for melanoma metastatic to the gastrointestinal tract. Br J Surg (1990) 1.06
The detection of minimal numbers of contaminating epithelial tumor cells in blood or bone marrow: use, limitations and future of RNA-based methods. Ann Oncol (1998) 1.06
Absence of oncogene amplifications and occasional activation of N-ras in lymphoblastic leukemia of childhood. Blood (1986) 1.06
Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging (2012) 1.05
Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response. Breast Cancer Res Treat (2013) 1.05
Management of intermediate-prognosis germ-cell cancer: results of a phase I/II study of Taxol-BEP. Int J Cancer (1999) 1.05
History of sentinel node and validation of the technique. Breast Cancer Res (2001) 1.05
Single intralesional tracer dose for radio-guided excision of clinically occult breast cancer and sentinel node. Ann Surg Oncol (2001) 1.04
Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy. Ann Oncol (2012) 1.04
Hereditary nonpolyposis colorectal cancer: results of long-term surveillance in 50 families. Eur J Cancer (1995) 1.04
Evaluation of (111)In-pentetreotide, (131)I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease. Nucl Med Commun (2002) 1.04
Overexpression of the p53 tumor suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking. Am J Surg Pathol (1993) 1.04
Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. Br J Cancer (1994) 1.03
High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma. J Pharm Biomed Anal (1990) 1.03
Increased risk of lung cancer, non-Hodgkin's lymphoma, and leukemia following Hodgkin's disease. J Clin Oncol (1989) 1.01
Toxicity grading systems. A comparison between the WHO scoring system and the Common Toxicity Criteria when used for nausea and vomiting. Ann Oncol (1994) 1.00
Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody. Cancer Immunol Immunother (1991) 0.99
A rapid and simple procedure for the routine detection of ras point mutations in formalin-fixed, paraffin-embedded tissues. Diagn Mol Pathol (1992) 0.99
Controversies and consensus in the diagnosis, work-up and treatment of gastric lymphoma: an international survey. Ann Oncol (1999) 0.98
VWF release and platelet aggregation in human melanoma after perfusion with TNF alpha. J Pathol (1995) 0.98
Probabilities for a probabilistic network: a case study in oesophageal cancer. Artif Intell Med (2002) 0.98
Comparative analysis of p53 gene mutations and protein accumulation in human non-small-cell lung cancer. Int J Cancer (1995) 0.98
In vitro migratory capacity of CD34+ cells is related to hematopoietic recovery after autologous stem cell transplantation. Blood (2001) 0.98
Lymphatic mapping and sentinel lymph node biopsy in breast cancer. Eur J Nucl Med (1999) 0.97
Altered lymphatic drainage after lymphadenectomy or radiotherapy of the axilla in patients with breast cancer. Br J Surg (1996) 0.97
Vascular complications of isolated limb perfusion. Eur J Surg Oncol (1998) 0.97
Reliability of lymphoscintigraphy in indicating the number of sentinel nodes in melanoma patients. Ann Surg Oncol (2000) 0.96
Resistance to cisplatin and analogues: mechanisms and potential clinical implications. Cancer Chemother Pharmacol (1988) 0.96
Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions. Arch Surg (1995) 0.96
Treatment results of primary stage I and II non-Hodgkin's lymphoma of the stomach. Radiother Oncol (1988) 0.96
Sentinel node biopsy for melanoma in the head and neck region. Head Neck (2000) 0.96
Reactivity to human papillomavirus type 16 L1 virus-like particles in sera from patients with genital cancer and patients with carcinomas at five different extragenital sites. Br J Cancer (2003) 0.95
Expression of adhesion molecules on CD34+ cells: CD34+ L-selectin+ cells predict a rapid platelet recovery after peripheral blood stem cell transplantation. Blood (1995) 0.94
A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide. J Pharmacokinet Pharmacodyn (2001) 0.94
Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer (1999) 0.94
Catheter-related complications in 52 patients treated with continuous infusion of low dose recombinant interleukin-2 via an implanted central venous catheter. Eur J Surg Oncol (1994) 0.94
N- and KRAS mutations in primary testicular germ cell tumors: incidence and possible biological implications. Genes Chromosomes Cancer (1995) 0.94
Prognostic significance of serum fragments of cytokeratin 19 measured by Cyfra 21-1 in cervical cancer. Gynecol Oncol (1994) 0.93